2006年，CRTD作为德国研究基金会（DFG FZ 111）的研究中心成立，同年被联邦卓越计划授予卓越集群（EXC 168）称号。2012年，CRTD被确认为DFG研究中心和卓越集群，为期五年。2019年，CRTD由德累斯顿工业大学和萨克森自由州资助接管。
德累斯顿再生疗法中心（CRTD）的研究重点是发现细胞和组织再生的原理，并利用它来识别、治疗和逆转疾病。CRTD凭借其在模式生物、器官和疾病系统的多样性以及从基础研究到验证项目和临床研究的一系列方法论方法，为应对这一挑战做好了准备。CRTD将工作台与诊所，将科学家与临床医生联系起来，将干细胞，基因编辑和再生方面的专业知识带到代谢，骨血液学和神经系统疾病的创新疗法中。
CRTD的研究目的是获得对干细胞生物学和组织再生的基本了解，并利用这些知识开发更好的疾病模型，并为人类健康的新诊断和疗法奠定基础。CRTD利用具有不同再生能力的多种模式生物，使用比较生物学方法识别给定组织中关键的促再生和抗再生因子和途径，并且这些分子靶点反过来又可用于开发新的治疗方法。CRTD的四个核心研究领域分别为血液学/免疫学、糖尿病、神经退行性疾病和组织再生。在这些研究领域中，CRTD及其在CRTD成员组中的合作伙伴进行基础研究，以确定新的治疗潜力，并在转化研究项目中进一步发展。除了为临床研究中的测试提供基础外，这些计划还产生了创新的研究工具和转移到商业的策略。
In 2006, CRTD was established as a research centre of the German Research Foundation (DFG FZ 111) and in the same year was awarded the Cluster of Excellence (EXC 168) title by the Federal Programme of Excellence. In 2012, CRTD was confirmed as a DFG Research Center and Cluster of Excellence for a period of five years. In 2019, CRTD was taken over with funding from the Technical University of Dresden and the Free State of Saxony.
Research at the Center for Regenerative Therapy in Dresden (CRTD) focuses on discovering the principle of cell and tissue regeneration and using it to identify, treat and reverse diseases. CRTD is well positioned to meet this challenge with its diversity in model organisms, organs and disease systems and a range of methodological approaches from basic research to validation projects and clinical studies. CRTD connects the workbench with the clinic, linking scientists with clinicians, bringing expertise in stem cells, gene editing and regeneration to innovative therapies for metabolic, osteopathology and neurological diseases.
CRTD's research aims to gain a basic understanding of stem cell biology and tissue regeneration and use this knowledge to develop better disease models and lay the foundation for new diagnoses and therapies for human health. CRTD uses a variety of model organisms with different regenerative capabilities to identify key pro-regeneration and anti-regeneration factors and pathways in a given tissue using comparative biological approaches, and these molecular targets can in turn be used to develop new therapeutics. CRTD's four core research areas are hematology/immunology, diabetes, neurodegenerative diseases, and tissue regeneration. In these areas of research, CRTD and its partners in the CRTD member group conduct basic research to identify new therapeutic potential for further development in translational research projects. In addition to providing the basis for testing in clinical studies, these initiatives have resulted in innovative research tools and strategies for transfer to commerce.